Best of ASCO - 2014 Annual Meeting

 

Welcome

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2019 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

NTRK1 fusion identified by capture-based next-generation sequencing in non-small-cell lung cancer.

Sub-category:
Metastatic Non-Small Cell Lung Cancer

Category:
Lung Cancer—Non-Small Cell Metastatic

Meeting:
2019 ASCO Annual Meeting

Abstract No:
e20664

Citation:
J Clin Oncol 37, 2019 (suppl; abstr e20664)

Author(s): Ruiying Zhao, Chan Xiang, Nan Dong, Lianying Guo, Shengji Ma, Yuchen Han; Department of Pathology, Shanghai Chest Hospital., Shanghai, China; Department of Pathology, Shanghai Chest hospital, Shanghai, China

Abstract Disclosures

Abstract:

Background: The clinicopathological features and genomic rearrangements of neurotrophic tyrosine kinase receptors (NTRKs) fusion in non-small-cell lung cancer (NSCLC) have not been fully identified. To explore NTRK1 fusion in non-small-cell lung cancer (NSCLC) specimens, and to explore the relationships between the NTRK1 fusion and the clinicopathological features and to identify genomic rearrangements by multiple molecular methods. Methods: In total, 3947 NSCLC specimens were tested for NTRK1 fusion using genomic DNA capture-based NGS. Then, these NTRK1 fusion cases were identified by Oncomine Focus Assay and FISH. The clinicopathological features were analyzed. Results: In total, five specimens (0.13%) were detected NTRK1 fusion. All these five specimens were adenocarcinoma (0.15%, 5/3423), while no NTRK1 fusions were found in 496 squamous cell carcinoma (SCC) cases and 28 adenosquamous carcinoma (ASC) cases. The ages of patients carried NTRK fusion were range from 31-year to 64-year-old. These five NTRK1 fusion cases were two females and three males, four non-smokers and one with 30 years smoking history, three surgical specimens and two small biopsies. Among these three surgical specimens, one was minimally invasive adenocarcinoma and two were invasive adenocarcinoma. One canonical fusion (TPM3-NTRK1) was detected, the other four were noncanonical fusion type (C14orf2-NTRK1, RRNAD1-NTRK1, LOC101060524-NTRK1, ARHGEF11-NTRK1). The RRNAD1-NTRK1 case was coexist with L858R mutation of EGFR, and the ARHGEF11-NTRK1 was coexist with G12A mutation of KRAS. All of these five fusions were confirmed by FISH, while only the canonical TPM3-NTRK1 was confirmed by Oncomine Focus Assay. Conclusions: In summary, NTRK1 fusion is rare in lung adenocarcinoma and does not exist in squamous cell carcinoma or adenosquamous carcinoma cases. Age and gender are not significantly correlated with NTRK1 fusion. NTRK1 fusions were more common in non-smokers. Genomic DNA capture-based NGS can detect both canonical and noncanonical NTRK1 genomic rearrangements. Noncanonical NTRK1 genomic rearrangements need confirmed by other methods such as FISH. NTRK1 fusion may coexist with other canonical driver gene mutation.

 
Other Abstracts in this Sub-Category:

 

1. Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

Meeting: 2019 ASCO Annual Meeting Abstract No: 102 First Author: Ferdinandos Skoulidis
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

2. Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).

Meeting: 2019 ASCO Annual Meeting Abstract No: 110 First Author: Sean Khozin
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

3. RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 9000 First Author: Kazuhiko Nakagawa
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

More...